Copyright 2016, American College of Chest Physicians. All Rights Reserved.
SESSION TITLE: Late-Breaking Abstracts: Lung Cancer Mechanisms
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Sunday, April 17, 2016 at 08:30 AM - 09:30 AM
PURPOSE: Long non-coding RNAs (lncRNAs) have emerged recently as major players in tumor biology and may be used for cancer diagnosis, prognosis, and potential therapeutic targets. Although down-regulation of lncRNA LOC285194 in several cancer types has been claimed, its role in lung cancer remains unknown. The aim of our study is to investigate the expression and clinical significance of lncRNA LOC285194 in non small cell lung cancer.
METHODS: The expression of lncRNA LOC285194 was detected by quantitative real-time PCR (qRT-PCR) in 66 pairs of tumor tissues and adjacent non-tumor tissues of lung cancer patients. Then, we analyzed the lncRNA LOC285194 expression levels against clinicopathological features and survival status in lung cancer. The proliferation, apoptosis, invasion and migration ability of A549 and H1299 cells with LOC285194 force expression were examined. NSCLC cells transfected with pCDNA-LOC285194 were injection into nude mice to investigate the effect of LOC285194 on tumorigenesis in vivo.
RESULTS: We found that lncRNA LOC285194 expression was down-regulated in tumor tissues compared with adjacent non-tumor tissues which was associated with tumor size. Kaplan-Meier analysis showed that patients with low lncRNA LOC285194 expression had a poor overall survival than those with high lncRNA LOC285194 expression. Moreover, univariate and multivariate analyses showed that low lncRNA LOC285194 expression was an independent poor prognostic factor for lung cancer patients. Overexpression of LOC285194 inhibited NSCLC cell proliferation, invasion and migration in vitro and in vivo. The growth inhibition by LOC285194 may be partially through the interaction with p53 protein.
CONCLUSIONS: Our results provided the first evidence that lncRNA LOC285194 might be a novel prognostic tumor-suppressing indicator in lung cancer and molecular mechanisms of lncRNA LOC285194 that involved in lung cancer need to be further studied.
CLINICAL IMPLICATIONS: The study indicates that lncRNA LOC285194 is down-regulated in lung cancer tissues and might be an independent molecular biomarker for predicting the prognosis of lung cancer patients. This new findings indicated that lncRNA LOC285194 may be used as a potential target for diagnosis and gene therapy of lung cancer. However, the precise molecular mechanisms of lncRNA LOC285194 that involved in lung cancer need to be further studied.
DISCLOSURE: The following authors have nothing to disclose: Xiaoshun Shi, Yaoqi Chen, Jingyi Chen, Fenglan Feng, Jin Li, Jianxing He
No Product/Research Disclosure Information
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.